CORXEL Pharmaceuticals, a portfolio company of RTW Biotech Opportunities (RTW), has had a new drug application accepted by China’s National Medical Products Administration (NMPA). The application acceptance is for the use of Aficamten for the treatment of obstructive hypertrophic cardiomyopathy (HCM). RTW describes Aficamten as “an investigational, next-in-class selective small molecule cardiac myosin inhibitor”. The … Continue reading Application for RTW Biotech Opportunities’ CORXEL’s Aficamten accepted by Chinese regulator